STOCK TITAN

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.

Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.

Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.

Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.

Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.

Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.

Rhea-AI Summary
Abbott launches Freedom 2 Save blueprint to help companies create student loan benefit programs. 91% of young adults with student loans report financial stress impacting their wellness. 94% interested in employer-provided 401(k) contribution while paying off loans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary
Abbott announces positive results from the LIFE-BTK clinical trial, demonstrating the effectiveness of its Esprit BTK Everolimus Eluting Resorbable Scaffold System in treating chronic limb-threatening ischemia (CLTI). The trial showed that Esprit BTK reduces disease progression and improves medical outcomes compared to the current standard of care. Abbott plans to submit the device for FDA review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
-
Rhea-AI Summary
Abbott is working hard to bring health and technology together to help people understand their health better. They aim to give individuals more control over managing their health by providing data and information. Abbott's technologies, such as continuous glucose monitors and virtual clinics, are already helping people improve their health. They are committed to advancing better health for more people and making health technology the most helpful technology of all.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
Rhea-AI Summary
Abbott presents new data at TCT 2023 showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease. The data confirm the safety, effectiveness, and improvements in quality of life when using TriClip for tricuspid regurgitation and MitraClip for mitral regurgitation. The studies highlight significant reductions in regurgitation and improvements in patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
-
Rhea-AI Summary
Abbott is working to expand access to its continuous glucose monitoring technology for people with diabetes. The FreeStyle Libre system eliminates routine fingersticks and provides real-time access to glucose numbers. Abbott has already improved the lives of over 5 million people with diabetes, but there is still a large population that could benefit from the technology. Medicare in the US and the French health authorities have expanded coverage for Abbott's technology, and other countries are following suit. Abbott is focused on making its technology accessible and affordable to as many people as possible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
Rhea-AI Summary
Fortune honors Abbott for groundbreaking Freedom 2 Save program, promoting financial wellness for employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
Rhea-AI Summary
Abbott reports Q3 2023 financial results with sales of $10.1 billion. Organic sales growth for underlying base business is 13.8%. Full-year 2023 EPS guidance range narrowed. Abbott acquires Bigfoot Biomedical and expands collaboration with mAbxience Holdings. Investments made during the pandemic drive broad-based growth. Abbott on track to deliver financial commitments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.71%
Tags
-
Rhea-AI Summary
Abbott to announce Q3 2023 financial results on Oct. 18 before market opens. Earnings conference call at 8am Central time. Webcast accessible through Abbott's Investor Relations website. Archived edition of the call available later.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
-
Rhea-AI Summary
Abbott releases 2022 Global Sustainability Report, highlighting efforts to improve access and affordability of life-saving technologies. They introduced new health technologies at lower prices, reduced emissions, and achieved zero waste at 6 sites. Positive impact on stock price expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
Rhea-AI Summary
Abbott completes acquisition of Bigfoot Biomedical, expanding presence in diabetes care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags

FAQ

What is the current stock price of Abbott Laboratories (ABT)?

The current stock price of Abbott Laboratories (ABT) is $114.23 as of December 20, 2024.

What is the market cap of Abbott Laboratories (ABT)?

The market cap of Abbott Laboratories (ABT) is approximately 196.0B.

What does Abbott Laboratories specialize in?

Abbott Laboratories specializes in cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

What are some of Abbott’s recent product launches?

Recent product launches include the PROTALITY™ high-protein nutrition shake and the TriClip™ system for tricuspid valve repair.

How much of Abbott’s sales are generated outside the United States?

Approximately 60% of Abbott’s sales are generated outside the United States.

What is Abbott’s PROTALITY™ brand?

The PROTALITY™ brand is a high-protein nutrition shake designed to support weight loss while preserving muscle mass, addressing global health challenges like obesity.

How does Abbott support global health initiatives?

Abbott supports global health initiatives through strategic partnerships like their collaboration with the Real Madrid Foundation to reduce childhood malnutrition and promote healthy habits.

What is Abbott’s financial performance like?

Abbott has demonstrated robust financial performance, with strong Q1 2024 results and a consistent track record of dividend payouts, evidenced by its inclusion in the S&P 500 Dividend Aristocrats Index.

How many employees does Abbott have?

Abbott employs over 114,000 people worldwide.

Which continuous glucose monitoring system is Abbott known for?

Abbott is known for its FreeStyle Libre continuous glucose monitoring systems, which are widely recognized for their innovation in diabetes management.

What is Abbott's mission?

Abbott's mission is to help people live more fully at all stages of life by developing life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines.

In how many countries does Abbott operate?

Abbott operates in more than 160 countries worldwide.

Abbott Laboratories

NYSE:ABT

ABT Rankings

ABT Stock Data

196.01B
1.72B
0.53%
77.7%
0.69%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
ABBOTT PARK